Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

Cancer. 1989 Dec 15;64(12):2420-3. doi: 10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>;2-b.


Ninety-nine patients with primary recurrent malignant tumors of the central nervous system were treated with procarbazine as a single agent. Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols. All patients had been treated previously with radiotherapy and 96 patients had also received previous chemotherapy. Twenty-five patients were treated at the first progression of their tumor, 47 were treated at the second progression, and 27 were treated at the third progression of their tumor. For the aggregate, the response plus stabilization rate was 27% for glioblastoma multiforme with median time to tumor progression of 30 weeks, and 28% for other anaplastic gliomas with a median time to tumor progression of 49 weeks. With respect to the percent of patients who responded or stabilized to treatment, these results are inferior to those reported previously for patients treated with procarbazine at recurrence. With respect to duration of response and stabilization, the data are comparable.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Brain Neoplasms / drug therapy*
  • Child
  • Child, Preschool
  • Female
  • Glioblastoma / drug therapy*
  • Glioma / drug therapy*
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Procarbazine / adverse effects
  • Procarbazine / therapeutic use*
  • Retrospective Studies
  • Spinal Cord Neoplasms / drug therapy*


  • Procarbazine